Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Is Marked by a Higher Frequency of Th17 Cells in the Liver and an Increased Th17/Resting Regulatory T Cell Ratio in Peripheral Blood and in the Liver
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease is increasing in prevalence. It can be subdivided into nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). Five to twenty percent of cases progress from NAFL to NASH. Increased hepatic Th17 cells and IL-17 expression were observed in NASH mice and patients, respectively. We analyzed CD4+ effector T cells and regulatory T cells (Tregs) from peripheral blood and livers of NAFL and NASH patients. A total of 51 NAFL patients, 30 NASH patients, 31 nonalcoholic fatty liver disease patients (without histology), and 43 healthy controls were included. FACS analysis was performed on PBMCs and intrahepatic lymphocytes. Compared with healthy controls, a lower frequency of resting Tregs (rTregs; CD4+CD45RA+CD25++) and higher frequencies of IFN-γ+ and/or IL-4+ cells were detected among CD4+ T cells of peripheral blood in NASH, and to a lesser degree in NAFL. In hepatic tissue, NAFL to NASH progression was marked by an increase in IL-17+ cells among intrahepatic CD4+ T cells. To define immunological parameters in peripheral blood to distinguish NAFL from NASH, we calculated different ratios. Th17/rTreg and Th2/rTreg ratios were significantly increased in NASH versus NAFL. The relevance of our findings for NASH pathogenesis was highlighted by the normalization of all of the changes 1 y after bariatric surgery. In conclusion, our data indicate that NAFL patients show changes in their immune cell profile compared with healthy controls. NAFL to NASH progression is marked by an increased frequency of IL-17+ cells among intrahepatic CD4+ T cells and higher Th17/rTreg and Th2/rTreg ratios in peripheral blood.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“with similar trends in CCL5+HOPX+ TH1 cells in both compartments and RTKN2+CCR7lo memory Treg cells in the liver (Fig. 5g)”
In the citing paper
“we observed a positive correlation of CD45RO+SELLhi CD4+ TCM cells and KLRB1+RORC+ TH17 cells in both liver and blood with fibrosis”
In the citing paper
“We found a marked increase in proinflammatory TH1 cell and TH17 cell frequency and function with MASH in the liver and peripheral blood, consistent with previous reports32,33, alongside an increase in RTKN2+CCR7lo memory Treg cells”
In the citing paper
“CD4 + T H 17 cells and CD8 + T cells have been shown to mediate NASH-associated liver fibrosis in both mice and humans (5-9).”
From NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosis (2023) · cites this paper as [8]
Citations
Cites
Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., & Stockinger, B. (2006) · Immunity · doi:10.1016/j.immuni.2006.01.001 · Cited by 3,605 · cited 1×
“whereas TGF-b alone induces Tregs instead of Th17 cells (6, 7).”
BackgroundAngulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,203 · cited 1×
“3 (13) Elevated alkaline phosphatase (% [n]) 9.”
Miyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.019 · Cited by 2,291
The utility of radiological imaging in nonalcoholic fatty liver disease
Saadeh, S., Younossi, Z. M., Remer, E. M., Gramlich, T., Ong, J. P., Hurley, M., Mullen, K. D., Cooper, J. N., & Sheridan, M. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.35354 · Cited by 2,110 · cited 1×
“Eight-one patients had histology-proven NAFL or NASH, and 31 patients were diagnosed with NAFLD by typical ultrasound findings, as described by sonographic NASH score (11).”
MethodThe Biological Functions of T Helper 17 Cell Effector Cytokines in Inflammation
Ouyang, W., Kolls, J. K., & Zheng, Y. (2008) · Immunity · doi:10.1016/j.immuni.2008.03.004 · Cited by 1,700 · cited 4×
“The inflammatory process underlying NASH is characterized by elevated expression of inflammatory cytokines, such as TNF-a and IL-6.”
InfluentialBrunt, E. M., Kleiner, D. E., Wilson, L. A., Belt, P., & Neuschwander-Tetri, B. A. (2011) · Hepatology · doi:10.1002/hep.24127 · Cited by 1,251
Standardizing immunophenotyping for the Human Immunology Project
Maecker, H. T., McCoy, J. P., & Nussenblatt, R. (2012) · Nature Reviews Immunology · doi:10.1038/nri3158 · Cited by 1,176 · cited 1×
“To determine whether the liver-infiltrating T cells are recently activated cells, we stained for HLA-DR expression (19).”
BackgroundLi, M. O., Sanjabi, S., & Flavell, R. A. (2006) · Immunity · doi:10.1016/j.immuni.2006.07.011 · Cited by 805
The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease
Gadd, V. L., Skoien, R., Powell, E. E., Fagan, K. J., Winterford, C., Horsfall, L., Irvine, K., & Clouston, A. D. (2014) · Hepatology · doi:10.1002/hep.26937 · Cited by 452 · cited 1×
“Cells expressing several T cell markers were recently identified by immunostaining in NAFLD liver biopsy sections (20).”
BackgroundThe interleukin-17 pathway is involved in human alcoholic liver disease # †
Lemmers, A., Moreno, C., Gustot, T., Maréchal, R., Degré, D., Demetter, P., de Nadai, P., Geerts, A., Quertinmont, E., Vercruysse, V., et al. (2009) · Hepatology · doi:10.1002/hep.22680 · Cited by 394
Cited by
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
“2546 Cell 184, May 13, 2021 quency of resting Tregs (rTregs; CD4 CD45RACD25) and higher frequencies of IFN-g and/or IL-4 cells in the circulation of individuals with NASH (Rau et al., 2016).”
BackgroundLiver inflammation and fibrosis
Koyama, Y., & Brenner, D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88881 · Cited by 1,295
“Necroptosis, as defined by RIP3-dependent mixedlineage kinase domain-like protein activation, is triggered in the liver of mouse models of NASH and in human NAFLD, whereas absence of RIP3 ameliorates liver injury, steatosis, inflammation, and fibrosis in an experimental NASH model (17).”
BackgroundInfluentialGut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
Aron-Wisnewsky, J., Vigliotti, C., Witjes, J., Le, P., Holleboom, A. G., Verheij, J., Nieuwdorp, M., & Clément, K. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0269-9 · Cited by 1,063
Immune cell-mediated features of non-alcoholic steatohepatitis
Huby, T., & Gautier, E. L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00639-3 · Cited by 573
Peiseler, M., Schwabe, R., Hampe, J., Kubes, P., Heikenwälder, M., & Tacke, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.012 · Cited by 564
Adaptive immunity: an emerging player in the progression of NAFLD
Sutti, S., & Albano, E. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0210-2 · Cited by 374
Insights into the Role and Interdependence of Oxidative Stress and Inflammation in Liver Diseases
Li, S., Hong, M., Tan, H.-Y., Wang, N., & Feng, Y. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/4234061 · Cited by 368
“blood and in the liver were also increased [96].”
BackgroundXu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 359
“Increased Th17 cells and expression of IL-17A are markers of progression from NAFL to NASH.(386,387) CD4 T cells may also Fig.”
BackgroundRau, M., Rehman, A., Dittrich, M., Groen, A. K., Hermanns, H. M., Seyfried, F., Beyersdorf, N., Dandekar, T., Rosenstiel, P., & Geier, A. (2018) · United European Gastroenterology Journal · doi:10.1177/2050640618804444 · Cited by 334
Self-citationTissue Immune Cells Fuel Obesity-Associated Inflammation in Adipose Tissue and Beyond
Liu, R., & Nikolajczyk, B. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01587 · Cited by 303
“This interaction emphasizes how bridges between classically defined innate and adaptive immune responses regulate inflammation and thereby hepatic deterioration in NAFLD.”
BackgroundInfluentialJi, Y., Gao, Y., Chen, H., Yin, Y., & Zhang, W. (2019) · Nutrients · doi:10.3390/nu11092062 · Cited by 288
“Currently, the prevalence rate of NAFLD is estimated to be 24% around the world, among which 5–20% of patients with simple steatosis progress to nonalcoholic steatohepatitis (NASH) [3,4].”
BackgroundMouse models of nonalcoholic steatohepatitis in preclinical drug development
Hansen, H. H., Feigh, M., Veidal, S. S., Rigbolt, K. T., Vrang, N., & Fosgerau, K. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.06.007 · Cited by 270
The Alterations in and the Role of the Th17/Treg Balance in Metabolic Diseases
Zhang, S., Gang, X., Yang, S., Cui, M., Sun, L., Li, Z., & Wang, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.678355 · Cited by 263
“An increased number of Th17 cells has been reported in the liver tissues of patients with NASH compared with healthy individuals (114).”
BackgroundBile acids and their receptors in metabolic disorders
Fiorucci, S., Distrutti, E., Carino, A., Zampella, A., & Biagioli, M. (2021) · Progress in Lipid Research · doi:10.1016/j.plipres.2021.101094 · Cited by 258
Giles, D. A., Moreno-Fernandez, M. E., Stankiewicz, T. E., Graspeuntner, S., Cappelletti, M., Wu, D., Mukherjee, R., Chan, C. C., Lawson, M. J., Klarquist, J., et al. (2017) · Nature Medicine · doi:10.1038/nm.4346 · Cited by 242
The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity
Van Herck, M. A., Weyler, J., Kwanten, W. J., Dirinck, E. L., De Winter, B. Y., Francque, S. M., & Vonghia, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00082 · Cited by 238
“in peripheral blood, nor in liver parenchyma (41).”
BackgroundInfluentialImmunological mechanisms and therapeutic targets of fatty liver diseases
Wang, H., Mehal, W., Nagy, L. E., & Rotman, Y. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00579-3 · Cited by 221
Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
Parola, M., & Pinzani, M. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101231 · Cited by 218
Barrow, F., Khan, S., Fredrickson, G., Wang, H., Dietsche, K., Parthiban, P., Robert, S., Kaiser, T., Winer, S., Herman, A., et al. (2021) · Hepatology · doi:10.1002/hep.31755 · Cited by 210
Novel therapeutic targets for cholestatic and fatty liver disease
Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204
Type I Interferon Responses Drive Intrahepatic T Cells to Promote Metabolic Syndrome
Ghazarian, M., Revelo, X. S., Nøhr, M. K., Luck, H., Zeng, K., Lei, H., Tsai, S., Schroer, S. A., Park, Y. J., Chng, M. H. Y., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aai7616 · Cited by 190
Periodontitis, chronic liver diseases, and the emerging oral‐gut‐liver axis
Albuquerque‐Souza, E., & Sahingur, S. E. (2022) · Periodontology 2000 · doi:10.1111/prd.12427 · Cited by 158
Moreno-Fernandez, M. E., Giles, D. A., Oates, J. R., Chan, C. C., Damen, M. S. M. A., Doll, J. R., Stankiewicz, T. E., Chen, X., Chetal, K., Karns, R., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.04.018 · Cited by 150
Haas, J. T., Vonghia, L., Mogilenko, D. A., Verrijken, A., Molendi-Coste, O., Fleury, S., Deprince, A., Nikitin, A., Woitrain, E., Ducrocq-Geoffroy, L., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0076-1 · Cited by 155
Bhattacharya, M., & Ramachandran, P. (2023) · Nature Immunology · doi:10.1038/s41590-023-01551-9 · Cited by 148
Metabolic Targets in Nonalcoholic Fatty Liver Disease
Esler, W. P., & Bence, K. K. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.04.007 · Cited by 144
Yahoo, N., Dudek, M., Knolle, P., & Heikenwälder, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.033 · Cited by 137
Obesity and gastrointestinal cancer: the interrelationship of adipose and tumour microenvironments
O'Sullivan, J. N., Lysaght, J., Donohoe, C. L., & Reynolds, J. V. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0069-7 · Cited by 154
The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease
Sawada, K., Chung, H., Softic, S., Moreno-Fernandez, M. E., & Divanovic, S. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.009 · Cited by 139
Calvo, S. S.-C., Bharath, L. P., Pugh, G. H., SantaCruz-Calvo, L., Lenin, R. R., Lutshumba, J., Liu, R., Bachstetter, A. D., Zhu, B., & Nikolajczyk, B. S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00575-1 · Cited by 161
Nati, M., Haddad, D., Birkenfeld, A. L., Koch, C. A., Chavakis, T., & Chatzigeorgiou, A. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9339-2 · Cited by 144
The Influence of Sex Hormones in Liver Function and Disease
Kasarinaite, A., Sinton, M., Saunders, P. T. K., & Hay, D. C. (2023) · Cells · doi:10.3390/cells12121604 · Cited by 127
The Emerging Role of B Cells in the Pathogenesis of NAFLD
Barrow, F., Khan, S., Wang, H., & Revelo, X. S. (2021) · Hepatology · doi:10.1002/hep.31889 · Cited by 126
IFN-γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progression
Aqbi, H. F., Wallace, M., Sappal, S., Payne, K. K., & Manjili, M. H. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mir0917-351r · Cited by 126
Poch, T., Krause, J., Casar, C., Liwinski, T., Glau, L., Kaufmann, M., Ahrenstorf, A. E., Hess, L. U., Ziegler, A. E., Martrus, G., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.03.016 · Cited by 123
Pharmacologic inhibition of lipogenesis for the treatment of NAFLD
Esler, W. P., & Cohen, D. E. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2023.10.042 · Cited by 111
Crosstalk Between Liver Macrophages and Surrounding Cells in Nonalcoholic Steatohepatitis
Li, H., Zhou, Y., Wang, H., Zhang, M., Qiu, P., Zhang, M., Zhang, R., Zhao, Q., & Liu, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01169 · Cited by 114
“A proinflammatory phenotype of macrophages showed a close relationship with diverse T-cell subsets by secreting IL-6, TNFα, IL-1β, IL-12, and IL-23 in the pathogenesis of NAFLD (12).”
BackgroundInfluentialCD4+ T cell activation and inflammation in NASH-related fibrosis
Zhou, Y., Zhang, H., Yao, Y., Zhang, X., Guan, Y., & Zheng, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.967410 · Cited by 106
“Moreover, increased number of Th17 cells in circulation and the liver is also observed in NAFLD/NASH patients, accompanied with increased Th1 cells (64).”
BackgroundMagee, N., Zou, A., & Zhang, Y. (2016) · BioMed Research International · doi:10.1155/2016/5170402 · Cited by 107
Psoriasis and Systemic Inflammatory Disorders
Tashiro, T., & Sawada, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084457 · Cited by 104
Her, Z., Tan, J. H. L., Lim, Y.-S., Tan, S. Y., Chan, X. Y., Tan, W. W. S., Liu, M., Yong, K. S. M., Lai, F., Ceccarello, E., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.580968 · Cited by 97
“’s model compared to other NAFLD mouse models (including our HIL mouse model) may be explained by the presence of MYC oncogene in the former (11, 13, 30, 35).”
BackgroundResultIL-17 and IL-17-producing cells and liver diseases, with focus on autoimmune liver diseases
Beringer, A., & Miossec, P. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.06.008 · Cited by 108
Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems
Ross, T. T., Crowley, C., Kelly, K. L., Rinaldi, A., Beebe, D. A., Lech, M. P., Martinez, R. V., Carvajal-Gonzalez, S., Boucher, M., Hirenallur-Shanthappa, D., et al. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.06.001 · Cited by 94
Paquissi, F. C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01195 · Cited by 93
“The Role of iL-17 Axis, and Associated Signaling Pathways, in Liver Fibrogenesis and Cirrhosis The subtype 17 of T helper lymphocyte cells is increased in almost all chronic and fibrosing liver diseases, including ALD, such as autoimmune hepatitis (AIH) (50, 110, 111), primary sclerosing cholangitis (PSC) (112, 113),…”
BackgroundThe TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?
Gonzalez‐Sanchez, E., Vaquero, J., Fernández‐Barrena, M. G., Lasarte, J. J., Avila, M. A., Sarobe, P., Reig, M., Calvo, M., & Fabregat, I. (2021) · Cancers · doi:10.3390/cancers13133248 · Cited by 109
Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease
Kuchay, M. S., Choudhary, N. S., & Ramos‐Molina, B. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00951.2024 · Cited by 116
Maricic, I., Marrero, I., Eguchi, A., Nakamura, R., Johnson, C. D., Dasgupta, S., Hernandez, C. D., Nguyen, P. S., Swafford, A. D., Knight, R., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800614 · Cited by 92
Paquissi, F. C. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00490 · Cited by 94
“In a study with 94 subjects (30 with NASH, 31 with NAFLD, and 43 healthy controls), patients with NASH (and in less degree with steatosis) had a lower frequency of T regulatory cells in peripheral blood, in comparison with controls (30).”
BackgroundInfluentialRai, R. P., Liu, Y., Iyer, S. S., Liu, S., Gupta, B., Desai, C., Kumar, P., Smith, T., Singhi, A. D., Nusrat, A., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.05.047 · Cited by 86
Zhang, X., Lau, H. C.-H., & Yu, J. Q. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2024.100018 · Cited by 112
Liver Inflammation and Hepatobiliary Cancers
Leone, V., Ali, A., Weber, A., Tschaharganeh, D. F., & Heikenwälder, M. F. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.01.012 · Cited by 99
The “Domino effect” in MASLD: The inflammatory cascade of steatohepatitis
Mladenić, K., Lenartić, M., Marinović, S., Polić, B., & Wensveen, F. M. (2024) · European Journal of Immunology · doi:10.1002/eji.202149641 · Cited by 98
“Various studies that analyzed cells from the liver in advanced stages of the disease defined MASH as a “Type 3” inflammatory disease, marked by the production of the cytokine IL-17A by CD4 Th17-helper T cells [9–11].”
BackgroundCharacterization of the immune cell landscape of patients with NAFLD
Diedrich, T., Kummer, S., Galante, A., Drolz, A., Schlicker, V., Lohse, A. W., Kluwe, J., Eberhard, J. M., & Schulze zur Wiesch, J. (2020) · PLOS ONE · doi:10.1371/journal.pone.0230307 · Cited by 78
“However, that pattern was not observed in the peripheral blood of NASH patients compared to NAFL patients [37].”
ResultLack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling
Zheng, Q., Martin, R. C., Shi, X., Pandit, H., Yu, Y., Liu, X., Guo, W., Tan, M., Bai, O., Meng, X., et al. (2020) · Theranostics · doi:10.7150/thno.45988 · Cited by 73
“In clinical patients, the transition from steatosis to NASH has been demonstrated to be associated with hepatic infiltration of IL-17A-producing cells [20].”
BackgroundDallio, M., Sangineto, M., Romeo, M., Villani, R., Romano, A. D., Loguercio, C., Serviddio, G., & Federico, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010436 · Cited by 73
Su, X. B., Chen, S., Liu, J., Feng, Y., Han, E., Hao, X., Liao, M., Cai, J., Zhang, S., Niu, J., et al. (2023) · Obesity Reviews · doi:10.1111/obr.13646 · Cited by 89
“110,111 However, IL-17 can also enhance the integrity of the intestinal barrier by promoting the expression of tight junction proteins and antimicrobial peptides.”
BackgroundPeiseler, M., & Tacke, F. (2021) · Cancers · doi:10.3390/cancers13040730 · Cited by 71
Hirsova, P., Bamidele, A. O., Wang, H., Povero, D., & Revelo, X. S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.760860 · Cited by 70
“In agreement, a higher frequency of CD4 T cells expressing IFNg and IL-4 has been reported in the peripheral blood of patients with NASH compared with healthy individuals (63).”
BackgroundResultInfluentialImmunomodulatory functions of FXR
Fiorucci, S., Zampella, A., Ricci, P., Distrutti, E., & Biagioli, M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111650 · Cited by 70
Inada, Y., Mizukoshi, E., Seike, T., Tamai, T., Iida, N., Kitahara, M., Yamashita, T., Arai, K., Terashima, T., Fushimi, K., et al. (2018) · Hepatology · doi:10.1002/hep.30212 · Cited by 74
“However, the frequency of CD4+ T helper 17 cells has been reported to increase in patients with NASH compared with healthy subjects or patients with simple fatty liver(38); and as fatty acids in hepatocytes induce apoptosis in CD4+ T cells in liver tissue,(14) the results of our study were considered to sufficiently r…”
BackgroundPsoriasis and Cardiometabolic Diseases: Shared Genetic and Molecular Pathways
Piaserico, S., Orlando, G., & Messina, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169063 · Cited by 85
“NAFLD to (nonalcoholic steatohepatitis) NASH progression correlates with a higher frequency of IL-17(+) cells among liver CD4(+) T cells and higher Th17/resting Treg and Th2/resting Treg ratios in the blood [205].”
BackgroundT cells: Friends and foes in NASH pathogenesis and hepatocarcinogenesis
Ramadori, P., Kam, S., & Heikenwalder, M. (2022) · Hepatology · doi:10.1002/hep.32336 · Cited by 66
“of Tregs.[65] Accordingly, a recent experimental study showed a constant time- dependent increase of infiltrating Th17 cells in liver and WAT of obese mice fed a high- fat, high- fructose diet.”
ResultInfluentialWang, J., Hou, Y., Mu, L., Yang, M., & Ai, X. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113570 · Cited by 83
Hepatic Immune Microenvironment in Alcoholic and Nonalcoholic Liver Disease
Byun, J., & Yi, H. (2017) · BioMed Research International · doi:10.1155/2017/6862439 · Cited by 63
Campisano, S., la Colla, A. B., Echarte, S. M., & Chisari, A. N. (2019) · Nutrition Research Reviews · doi:10.1017/s0954422418000239 · Cited by 68
“In addition, different studies have reported that the progression to NASH is marked by an increment of the Th17:regulatory T cells (Tregs) ratio in peripheral blood and liver((156)).”
BackgroundYu, W., Sun, S., Yan, Y., Zhou, H., Liu, Z., & Fu, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1519925 · Cited by 82
Jeffery, H. C., Braitch, M. K., Brown, S., & Oo, Y. H. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00334 · Cited by 70
“Progression from non-alcoholic fatty liver to non-alcoholic steatohepatitis is characterized by a higher frequency of Th17 cells in the liver and an increased ratio of Th17/resting CD4+CD45RA+CD25high Treg in peripheral blood (11).”
BackgroundMoayedfard, Z., Sani, F., Alizadeh, A. A., Lankarani, K. B., Zarei, M., & Azarpira, N. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02929-6 · Cited by 61
“Low levels of hepatic Tregs in the high-fat diet model led to the suppression of inflammatory responses [91].”
BackgroundThe Detrimental Role of Regulatory T Cells in Nonalcoholic Steatohepatitis
Dywicki, J., Buitrago‐Molina, L. E., Noyan, F., Davalos‐Misslitz, A. C., Hupa‐Breier, K. L., Lieber, M., Hapke, M., Schlue, J., Falk, C. S., Raha, S., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1807 · Cited by 57
“(9) There is an association between increased T helper 17 immune responses and the severity of NASH(10,11) and a reduction of hepatic regulatory T cells (Tregs) in mice by apoptosis.”
BackgroundReprogramming of Hepatic Metabolism and Microenvironment in Nonalcoholic Steatohepatitis
Rui, L., & Lin, J. D. (2022) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-062220-105200 · Cited by 56
Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis
Chackelevicius, C. M., Gambaro, S. E., Tiribelli, C., & Rosso, N. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i41.9096 · Cited by 57
OX40 Regulates Both Innate and Adaptive Immunity and Promotes Nonalcoholic Steatohepatitis
Sun, G., Jin, H., Zhang, C., Meng, H., Zhao, X., Wei, D., Ou, X., Wang, Q., Li, S., Wang, T., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.12.006 · Cited by 57
Treating inflammation to combat non-alcoholic fatty liver disease
Wiering, L., & Tacke, F. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0194 · Cited by 56
The cellular pathways of liver fibrosis in non-alcoholic steatohepatitis
Méndez‐Sánchez, N., Valencia-Rodríguez, A., Coronel-Castillo, C. E., Vera-Barajas, A., Contreras-Carmona, J., Ponciano‐Rodríguez, G., & Zamora‐Valdés, D. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.02.184 · Cited by 57
“Interestingly, the progression of NAFLD to NASH has been associated with the liver accumulation of Th17 cells (117).”
BackgroundHatasa, M., Yoshida, S., Takahashi, H., Tanaka, K., Kubotsu, Y., Ohsugi, Y., Katagiri, T., Iwata, T., & Katagiri, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073728 · Cited by 65
“Studies involving humans have shown increased Th17 levels in the adipose tissue and peripheral blood in patients with obesity and type 2 diabetes, and patients with NASH have shown increased Th17 levels, similar to mice [108].”
BackgroundJee, Y.-M., Lee, J., & Ryu, T. (2025) · Biomedicines · doi:10.3390/biomedicines13051260 · Cited by 71
“Elevated Th17 cytokines (IL-17A/F and IL-22) have been linked to fibrosis progression, whereas Treg dysfunction contributes to the failure of inflammatory resolution [61].”
Ma, C., Zhang, Q., & Greten, T. F. (2017) · FEBS Journal · doi:10.1111/febs.14209 · Cited by 54
KLF10 Deficiency in CD4+ T Cells Triggers Obesity, Insulin Resistance, and Fatty Liver
Wara, A. K., Wang, S., Wu, C., Fang, F., Haemmig, S., Weber, B. N., Aydogan, C. O., Tesmenitsky, Y., Aliakbarian, H., Hawse, J. R., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108550 · Cited by 49
“…Teff to Treg ratios cause a predisposition to intrahepatic inflammation, fatty liver, and progression to NASH in both mice and human subjects (Bertola et al., 2010; Inzaugarat et al., 2011; Kremer et al., 2010; Pacifico et al., 2006; Rau et al., 2016; Sutti et al., 2015; Vonghia et al., 2015).”
Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma
Koo, S.-Y., Park, E.-J., & Lee, C.-W. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0480-3 · Cited by 47
From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment
Vidal, S., Puig, L., Carrascosa, J. M., González‐Cantero, Á., Ruiz‐Carrascosa, J., & Velasco-Pastor, A.-M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136740 · Cited by 48
“pathogenic role for the balance between Th17 and rTreg cells [75].”
BackgroundNian, F., Wu, L., Xia, Q., Tian, P., Ding, C., & Lu, X. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00415 · Cited by 96
Samy, A. M., Kandeil, M. A., Sabry, D., Abdel-Ghany, A. A., & Mahmoud, M. O. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30387 · Cited by 60
“Experimental studies have shown that reducing these cells can alleviate symptoms of NASH [71].”
BackgroundZhang, H., Jiang, Z., & Zhang, L. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.01.005 · Cited by 49
Non‐alcoholic fatty liver disease and psoriasis – is there a shared proinflammatory network?
Heitmann, J., Frings, V. G., Geier, A., Goebeler, M., & Kerstan, A. (2021) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14425 · Cited by 62
Self-citationMartin, O. P., Wallace, M. S., Oetheimer, C., Patel, H. B., Butler, E. C., Wong, L. P., Huang, P., Elbaz, J., Costentin, C., Salloum, S., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02255-y · Cited by 45
“…in proinflammatory T H 1 cell and T H 17 cell frequency and function with MASH in the liver and peripheral blood, consistent with previous reports 32,33 , alongside an increase in RTKN2 + CCR7 lo memory T reg cells, possibly as a feedback mechanism to reduce inflammation and suppress T cell…”
MASLD development: From molecular pathogenesis toward therapeutic strategies
Yang, Z., Zhao, J., Xie, K., Tang, C., Gan, C., & Gao, J. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003629 · Cited by 58
“[49] Cytotoxic CD8 + T cells were found to be related to MASH.”
Ilan, Y., Shailubhai, K., & Sanyal, A. (2018) · Clinical and Experimental Immunology · doi:10.1111/cei.13159 · Cited by 45
Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System
Torre, P., Motta, B. M., Sciorio, R., Masarone, M., & Persico, M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.781567 · Cited by 53
“In addition, an increase in activation of CD4+ T lymphocytes was documented both in peripheral blood and liver (based on the expression of HLA-DR) (226); Th17 was found to be more abundant in the liver of patients with NASH than in those with NAFL and in circulating blood of NASH patients Th17/Treg ratio was found to…”
BackgroundNascè, A., Gariani, K., Jornayvaz, F. R., & Szántó, I. (2022) · Antioxidants · doi:10.3390/antiox11061131 · Cited by 55
“In particular, an imbalance in the Th17/Treg lymphocyte populations was noted in a study that analyzed liver biopsies and peripheral blood samples of 31 NAFLD and 30 NASH patients and compared them to 43 healthy controls [156].”
ResultImmune–metabolic interactions in homeostasis and the progression to NASH
Hoogerland, J. A., Staels, B., & Dombrowicz, D. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.07.001 · Cited by 48
Inflammation in MASLD progression and cancer
Kim, Y. S., Park, Y., Rho, H., Yao, T., Gao, B., & Hwang, S. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101414 · Cited by 75
Lambrecht, J., & Tacke, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.634409 · Cited by 43
Stress kinases in the development of liver steatosis and hepatocellular carcinoma
Cicuéndez, B., Ruiz-Garrido, I., Mora, A., & Sabio, G. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101190 · Cited by 48
“Patients with NAFLD have an elevated number of Th2 cells in peripheral blood and a high Th2/Treg ratio, which decreases 12 months after bariatric surgery [136].”
BackgroundThe role of complement in nonalcoholic fatty liver disease
Guo, Z., Fan, X., Yao, J., Tomlinson, S., Yuan, G., & He, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1017467 · Cited by 51
“In addition, the progression from NAFL to NASH is marked by an increased Th17/resting Tregs ratio in the liver (80).”
BackgroundMarinović, S., Lenartić, M., Mladenić, K., Šestan, M., Kavazović, I., Benić, A., Krapić, M., Rindlisbacher, L., Cokarić Brdovčak, M., Sparano, C., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.add1599 · Cited by 43
Van Herck, M. A., Vonghia, L., Kwanten, W. J., Julé, Y., Vanwolleghem, T., Ebo, D. G., Michielsen, P. P., De Man, J. G., Gama, L., De Winter, B. Y., et al. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.04.010 · Cited by 43
Hepatocyte and immune cell crosstalk in non-alcoholic fatty liver disease
Trejo, A. M. C., Větvička, V., Vištějnová, L., Králíčková, M., & Montúfar, E. B. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1887730 · Cited by 43
Ishay, Y., Nachman, D., Khoury, T., & Ilan, Y. (2020) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00003.2020 · Cited by 42
Nagashimada, M., & Honda, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158008 · Cited by 43
“Notably, the intestinal IL-17 level was elevated in mice with steatohepatitis, and the number of Th17 cells was increased among peripheral blood mononuclear cells in patients with NASH [29,81].”
BackgroundThe gut mycobiome: a novel player in chronic liver diseases
Jiang, L., Stärkel, P., Fan, J.-G., Fouts, D. E., Bacher, P., & Schnabl, B. (2021) · Journal of Gastroenterology · doi:10.1007/s00535-020-01740-5 · Cited by 38
Metadata
- Authors
- Rau, M., Schilling, A.-K., Meertens, J., Hering, I., Weiss, J., Jurowich, C., Kudlich, T., Hermanns, H. M., Bantel, H., Beyersdorf, N., & Geier, A.
- Affiliations
- Universitätsklinikum Würzburg (DE)
- Medizinische Hochschule Hannover (DE)
- University of Würzburg (DE)
- Corresponding author
- Rau, Monika
- Meertens, Jan
- Hering, Ilona
- Weiss, Johannes
- Kudlich, Theodor
- Geier, Andreas
- ORCID
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-01-01
- Volume
- 196
- Issue
- 1
- Pages
- 97-105
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2219561900
- Cited by
- 302
- References
- 30
- Citations by year
- 2026: 14 · 2025: 54 · 2024: 33 · 2023: 34 · 2022: 40 · 2021: 46 · 2020: 29 · 2019: 13 · 2018: 18 · 2017: 11 · 2016: 9
- FWCI
- 9.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, disease progression, Th17 cells, regulatory T cells, IL-17, CD4+ T cells, Th1/Th2 balance, intrahepatic lymphocytes, bariatric surgery, liver inflammation
- MeSH terms
- Adult, Animals, Cells, Cultured, Female, Humans, Interferon-gamma, Liver, Male, Middle Aged, Prospective Studies, Interleukin-4, Th2 Cells, Disease Progression, Lymphocyte Count, Interleukin-17, Bariatric Surgery, T-Lymphocytes, Regulatory, Mice, Th17 Cells, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.